Previous Page
32
nanotimes
Companies Facts
“We are very fortunate to have the support of world’s leading glass producer, AGC (Asahi Glass Company) Group, and DFJ VTB Capital Aurora, a highly repu- table nanotechnology investor associated with one of the major Russia’s banking groups, VTB Group,” said Boris Kobrin, Founder and CEO of Rolith. “This in- vestment will allow us to scale up our nanostructuring technology to substrate areas larger than what is of- fered by any competitors and demonstrate feasibility of the first few of our nanostructured coatings.”
olar Junction, a developer of high efficiency multijunction cells for the concentrated photovol-
taic (CPV) market, closed its Series D financial round of $19.2m from current investors with an additional strategic investment and partnership from IQE. This investment and partnership is to scale up Solar Junction’s manufacturing of its world record cell of 43.5% efficiency.
Solar Junction is a manufacturer of high efficiency III-V multi-junction solar cells based on ASLAM™ materials (Adjustable Spectrum Lattice Matched). The A-SLAM™ architecture provides material band- gap tunability – particularly from 0.8 to 1.42 eV – to maximize the absorbed sunlight within CPV modules, thereby increasing the efficiency and energy har- vested.
Recently, the Stanford start-up netted the Most Inno- vative Device Award 2012 by Compound Semicon- ductor for its high efficiency SJ3 product.
pire Corporation (NASDAQ: SPIR) reported revenues from continuing operations for the year
ended December 31, 2011 of $61.6 million, a 22.8% decrease from $79.8 million in 2010. Net loss for the year ended December 31, 2011 was $1.5 million, or $0.18 per diluted share, compared to a net loss of $0.4 million, or $0.05 per diluted share, for the same period of 2010.
Spire’s revenues for the fourth-quarter ended De- cember 31, 2011 were $19.5 million from conti- nuing operations, an increase of 8.5% from $18.0 million in the fourth-quarter of 2010.
Roger G. Little, Chairman and CEO, stated “I am pleased with our revenue performance as evidenced by the top line growth on a quarter over quarter basis. Our Solar Business comprised 82% of our total revenue in 2011 which included the delivery of several Turn-Key Module Lines and a Back-End Thin Line along with increased volume for our high margin solar Simulators. The operating improvements are a result of the Company focusing on our core compe- tencies, continued process improvements for our PV equipment business, and pursuing cost containment measures.”
tarpharma Holdings Limited (ASX:SPL, OTCQX: SPHRY) announced the commencement of two
concurrent pivotal phase 3 clinical trials of VivaGel® for the treatment of bacterial vaginosis (BV), follow- ing receipt of ethics approval. • Two pivotal phase 3 trials launched for the treatment of bacterial vaginosis (BV);
12-03 :: March/April 2012